# UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

## FORM 8-K

#### **CURRENT REPORT**

Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 25, 2023

### INTEGRA LIFESCIENCES HOLDINGS CORPORATION

(Exact Name of Registrant as Specified in its Charter)

Delaware0-2622451-0317849(State or Other Jurisdiction of Incorporation or Organization)(Commission File Number)(IRS Employer Identification No.)

#### 1100 Campus Road Princeton, NJ 08540

(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code: (609) 275-0500

#### Not Applicable

(Former nan	me or former address, if changed since	last report)
Check the appropriate box below if the Form 8-K filing is in collowing provisions (see General Instruction A.2. below):		filing obligation of the registrant under any of the
☐ Written communications pursuant to Rule 425 under the	Securities Act (17 CFR 230.425).	
☐ Soliciting material pursuant to Rule 14a-12 under the Ex	schange Act (17 CFR 240.14a-12).	
Pre-commencement communications pursuant to Rule 1	4d-2(b) under the Exchange Act (17 C	CFR 240.14d-2(b)).
☐ Pre-commencement communications pursuant to Rule 1	3e-4(c) under the Exchange Act (17 C	FFR 240.13e-4(c)).
ecurities Registered Pursuant to Section12(b) of the Act:		
<b>Title of Each Class</b>	<b>Trading Symbol</b>	Name of Exchange on Which Registered
Common Stock, Par Value \$.01 Per Share	IART	Nasdaq Global Select Market
ndicate by check mark whether the registrant is an emerghapter) or Rule 12b-2 of the Securities Exchange Act of 19		Rule 405 of the Securities Act of 1933 (§230.405 of this
Emerging growth company		
f an emerging growth company, indicate by check mark if r revised financial accounting standards provided pursuant	_	_

# ITEM 5.02 DEPARTURE OF DIRECTORS OR CERTAIN OFFICERS; ELECTION OF DIRECTORS; APPOINTMENT OF CERTAIN OFFICERS; COMPENSATORY ARRANGEMENTS OF CERTAIN OFFICERS

On January 25, 2023, Carrie Anderson, Chief Financial Officer of Integra LifeSciences Holdings Corporation (the "Company"), notified the Company of her decision to resign, effective as of February 2, 2023, to pursue another professional opportunity.

The Company intends to commence a comprehensive search process to identify a new Chief Financial Officer. In the interim, Mathieu P. Aussermeier, Vice President, Corporate Finance, Investor Relations & Treasurer, and Jeffrey Mosebrook, Senior Vice President, Finance, will assume Ms. Anderson's financial duties and responsibilities and report to Jan De Witte, the Company's President and Chief Executive Officer. Mr. Aussermeier will be responsible for treasury, financial planning and analysis, and investor relations. Mr. Mosebrook will oversee accounting, tax, internal audit and global business services. During the interim period, Mr. Mosebrook will serve as the Company's principal financial officer in addition to serving as principal accounting officer.

Mr. Mosebrook's biographical information is described in the Company's definitive proxy statement filed with the Securities and Exchange Commission on April 8, 2022, which is incorporated herein by reference. There are no arrangements or understandings between Mr. Mosebrook and any other person that would require disclosure under Item 401(b) of Regulation S-K. Additionally, there is no family relationship between Mr. Mosebrook and any other person that would require disclosure under Item 401(d) of Regulation S-K and he is not a party to any transactions that would require disclosure under Item 404(a) of Regulation S-K.

#### **SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

#### INTEGRA LIFESCIENCES HOLDINGS CORPORATION

Date: January 25, 2023 By: <u>/s/ Eric I. Schwartz</u>

Eric I. Schwartz

Title: Executive Vice President, Chief Legal Officer and

Secretary